This is data obtained from the U.S. Centers for Disease Control and Prevention and several population-based cancer registries, published in JNCI, and includes a total of 2,670 patients. Data from U.S. cancer registries were used to evaluate the effectiveness of HPV vaccines for cancer prevention. The results found the distribution of HPV DNA in the following cancers: cervical, 90.6%; anal, 91.1%; vaginal, 75.0%; oropharyngeal, 70.1%; vulvar, 68.8%; penile, 63.3%; oral, 32.0%; laryngeal, 20.9%; and cervical carcinoma in situ, 98.8%. Vaccines targeting HPV 16/18 prevented the vast majority of cervical cancers (66.2%), anal cancers (79.4%), oropharyngeal cancers (60.2%), and vaginal cancers (55.1%), as well as many penile (47.9%) and vulvar (48.6%) cancers: a total of 14,858 cases per year. The newly available 9-valent vaccine (which can also target HPV 31/33/45/52/58) may also prevent an additional 4.2% to 18.3% of cancers: a total of 3,944 cases per year. For the vast majority of cancers, younger age at diagnosis is associated with a high prevalence of HPV 16/18. With the exception of oropharyngeal and cervical carcinoma in situ, the distribution of HPV 16/18 is similar across races and ethnicities. See Figures 2-4 for details. In summary, current vaccine applications reduce the vast majority of HPV-associated cancers in the United States, and the new nine-valent vaccine may be able to reduce another small percentage of cancers.